PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
Research output: Contribution to journal › Journal article › Research › peer-review
We recently described naturally occurring PD-L1-specific T cells that recognize PD-L1-expressing immune cells as well as malignant cells. In the present study, we investigated whether the immunogenicity of a dendritic cell (DC)-based vaccine could be influenced by co-stimulation with a known PD-L1-derived epitope. We incubated a PD-L1-derived peptide epitope (19 amino acids long) or a control peptide (an irrelevant HIV epitope) with peripheral blood mononuclear cells from patients with malignant melanoma who had received a DC-based vaccine. We observed a significantly higher number of T cells that reacted to the vaccine in cultures that had been co-stimulated with the PD-L1 peptide epitope compared to cultures incubated with control peptide. Next, we characterized a novel PD-L1-derived epitope (23 amino acids long) and found that co-stimulation with both PD-L1 epitopes boosted the immune response elicited by the DC vaccine even further. Consequently, we observed a significant increase in the number of vaccine-reacting T cells in vitro. In conclusion, activation of PD-L1-specific T cells may directly modulate immunogenicity of DC vaccines. Addition of PD-L1 epitopes may thus be an easily applicable and attractive option to augment the effectiveness of cancer vaccines and other immunotherapeutic agents.
Original language | English |
---|---|
Article number | e1202391 |
Journal | OncoImmunology |
Volume | 5 |
Issue number | 8 |
ISSN | 2162-4011 |
DOIs | |
Publication status | Published - 2 Aug 2016 |
- Anti-tregs, antigen, B7-H1, CD274, co-stimulation, dendritic cell-based vaccine, melanoma, PD-L1, T cells
Research areas
ID: 168929777